| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
Bax; Mcl-1; c-FLIP; COX-2
|
|---|---|
| ln Vitro |
After 24 hours of treatment, human kidney carcinoma Caki cells undergo disinfection induced by jaceosidin (30, 50, and 75 μM), but normal cells experience no discernible effects [1]. via suppressing NF-κB and/or Sp1 regulatory activity, Jaceosidin (75 μM) lowers MMP levels via activating Bax and releases cytochromes into Jaceosidin-induced cells to participate in Mcl-1, c-FLIP-mediated transcription [1]. In the cytoplasm of HES and HESC, jaceosidin is active [1]. After 48 hours of treatment, the inhibitory activity (IC50 values were 52.68 and 55.10 μM, respectively) and cytotoxicity (IC50 values were 70.54 and 147.14 μM, respectively) to Hec1 A and KLE were increased [2].
|
| ln Vivo |
Jaceosidin (10 and 20 mg/kg, once day for three days), used as a face increases in the amount of leukocytes and protein levels in nozzle coat exudates caused by burns carrageenan [3]. Jaceosidin (20 mg/kg po every two days, hourly) lessens the volume of edema in paws that are edematous [3]. /kg, po) suppresses NF-κB activator and COX-2 expression in mice [3]. Male BALB/c mice aged 5 weeks, weighing 23–26 g [3]
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Hec1A, KLE, HES and HESC Cell Tested Concentrations: 3.125, 6.25, 12.5, 25, 50 and 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated cytostatic activity against HES and HESC cells, IC50 is 52.68 and 55.10 μM, less cytotoxic Hec1 A and KLE (IC50, 70.54, 147.14 μM). |
| Animal Protocol |
Animal/Disease Models: 5weeks old male balb/c (Bagg ALBino) mouse (23-26 g)[3]
Doses: 10 and 20 mg/kg Route of Administration: P.O. one time/day for 3 days Experimental Results:diminished the volumes of exudates (inflammatory markers), cell number and protein levels. Inhibited TNF-α by 46.7% and 50.8%, IL-1β by 46.0% and 44.7%, and PGE2 by 21.7% and 16.9%, respectively, at 20 mg/kg. Blocked COX-2 expression and NF-κB activation. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats (180-200 g)[3] Doses: 20 mg/kg Route of Administration: P.O., for 2 hour Experimental Results:diminished hind paw edema volume by 27.1% at 1 h, and 24.0% at 2 h, respectively. |
| References |
[1]. Woo SM, et al. Jaceosidin induces apoptosis through Bax activation and down-regulation of Mcl-1 and c-FLIP expression in human renal carcinoma Caki cells. Chem Biol Interact. 2016 Dec 25;260:168-175.
[2]. Lee JG, et al. Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation. Food Chem Toxicol. 2013 May;55:214-21. [3]. Min SW, et al. Inhibitory effect of eupatilin and jaceosidin isolated from Artemisia princeps on carrageenan-induced inflammation in mice. J Ethnopharmacol. 2009 Sep 25;125(3):497-500. |
| Molecular Formula |
C17H14O7
|
|---|---|
| Molecular Weight |
330.2889
|
| Exact Mass |
330.07
|
| Elemental Analysis |
C, 61.82; H, 4.27; O, 33.91
|
| CAS # |
18085-97-7
|
| Related CAS # |
18085-97-7
|
| Appearance |
Solid powder
|
| SMILES |
COC1=C(C=CC(=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)OC)O)O
|
| InChi Key |
GLAAQZFBFGEBPS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O7/c1-22-13-5-8(3-4-9(13)18)12-6-10(19)15-14(24-12)7-11(20)17(23-2)16(15)21/h3-7,18,20-21H,1-2H3
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxychromen-4-one
|
| Synonyms |
Jaceosidin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 66~125 mg/mL (199.8~378.5 mM)
Ethanol: 6~7.1 mg/mL (18.2~21.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0276 mL | 15.1382 mL | 30.2764 mL | |
| 5 mM | 0.6055 mL | 3.0276 mL | 6.0553 mL | |
| 10 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
